Elevated Pharma · U.S.-based research company
Peptide research references
Research summaries, evidence limits and direct source links. Search a material or choose a research area.
Research summaries & sources
0 shown
TirzepatideDevelopment code: LY3298176Peptide analogFDA-labeled drug reference
A synthetic, acylated peptide analog that activates GIP and GLP-1 receptors. The database identity describes the reference substance, not any Elevated Pharma lot.
- Research summary
- Structural and receptor-pharmacology literature examines binding and signaling at GIP and GLP-1 receptors.
- Evidence limits
- An FDA-approved prescription product exists. That status does not transfer to an unlabeled research material, supplier source, or future Elevated Pharma product.
- U.S. context
- Current FDA prescribing information is the controlling source for the approved drug product. This informational record is not prescribing information.
Identity & technical details
- Identity status
- Reference identity defined
- Formula
- C225H348N48O68
- Molecular mass
- 4813 g/mol
- PubChem CID
- 166567236
Official & primary research sources
RetatrutideDevelopment code: LY3437943Peptide analogActive clinical research
An investigational peptide agonist studied at GIP, GLP-1, and glucagon receptors.
- Research summary
- Published phase 2 research and registered phase 3 studies examine this triple-receptor agonist in human clinical settings.
- Evidence limits
- Clinical-trial results do not establish the identity, quality, safety, or permitted use of an independently sourced material.
- U.S. context
- The cited records describe an investigational program. No FDA-approved product status is asserted by this library.
Identity & technical details
- Identity status
- Reference identity defined
Official & primary research sources
- Phase 2 retatrutide trialPUBMED
- Phase 3 retatrutide and tirzepatide study NCT06662383CLINICALTRIALS
Human chorionic gonadotropinAlso indexed as: hCGHormone / biologicFDA-labeled biologic reference
A heterodimeric glycoprotein hormone with alpha and beta subunits. It is not accurately represented as one small-molecule formula.
- Research summary
- Official labeling describes its biologic identity, subunit structure, and standardized potency convention.
- Evidence limits
- Mass alone does not establish hCG potency or equivalence. The source-list mass values are intentionally not reproduced in this library.
- U.S. context
- FDA-labeled hCG drug products express potency in USP units. This record does not represent or imply an approved Elevated Pharma product.
Identity & technical details
- Identity status
- Composition dependent
Official & primary research sources
GHRP-2Also indexed as: Growth hormone-releasing peptide 2 · Also indexed as: PralmorelinPeptide analogHuman research literature
A synthetic hexapeptide growth-hormone secretagogue used in endocrine research.
- Research summary
- Human studies have examined endocrine response to GHRP-2 in diagnostic and longitudinal research settings.
- Evidence limits
- Published endocrine responses do not provide a general safety conclusion or establish an independently sourced material's identity.
- U.S. context
- No approved-product or permitted-use claim is made by this reference record.
Identity & technical details
- Identity status
- Reference identity defined
- Formula
- C45H55N9O6
- Molecular mass
- 818 g/mol
- PubChem CID
- 6918245
Official & primary research sources
MOTS-cAlso indexed as: Mitochondrial open reading frame of the 12S rRNA-cPeptidePreclinical literature
A 16-residue mitochondrial-derived peptide first characterized in cellular and animal research.
- Research summary
- The original literature studies cellular signaling and metabolic phenotypes in cultured cells and mice.
- Evidence limits
- The cited work is preclinical and does not establish human safety, clinical effectiveness, or a material specification.
- U.S. context
- FDA has identified limited human safety information and potential immunogenicity concerns in the compounding context.
Identity & technical details
- Identity status
- Reference identity defined
- Sequence
- MRWQEMGYIFYPRKLR
- Formula
- C101H152N28O22S2
- Molecular mass
- 2174.6 g/mol
- PubChem CID
- 146675088
Official & primary research sources
GHK-CuAlso indexed as: Copper tripeptide-1 · Also indexed as: Copper glycyl-L-histidyl-L-lysineMetal-peptide complexPreclinical literature
A copper complex of the glycyl-L-histidyl-L-lysine tripeptide.
- Research summary
- Published laboratory and animal work includes copper-binding and tissue-repair models.
- Evidence limits
- Preclinical findings do not establish clinical benefit or the identity, oxidation state, purity, or suitability of a future lot.
- U.S. context
- FDA identifies route-dependent data gaps and potential safety concerns for compounded injectable GHK-Cu.
Identity & technical details
- Identity status
- Reference identity defined
- Sequence
- Gly-His-Lys
- Formula
- C14H21CuN6O4-
- Molecular mass
- 400.9 g/mol
- PubChem CID
- 139035031
Official & primary research sources
KPVAlso indexed as: Lys-Pro-Val · Also indexed as: Lysine-proline-valinePeptidePreclinical literature
A three-residue peptide with the sequence lysine-proline-valine.
- Research summary
- Published work includes peptide-transport experiments in cells and inflammatory models in mice.
- Evidence limits
- Cell and animal findings cannot be treated as human outcome evidence or as a combined-product claim.
- U.S. context
- FDA has identified insufficient human safety information and potential immunogenicity concerns in the compounding context.
Identity & technical details
- Identity status
- Reference identity defined
- Sequence
- Lys-Pro-Val
- Formula
- C16H30N4O4
- Molecular mass
- 342.43 g/mol
- PubChem CID
- 125672
Official & primary research sources
SelankAlso indexed as: Thr-Lys-Pro-Arg-Pro-Gly-ProPeptide analogPreclinical and analytical literature
A synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro.
- Research summary
- Published work includes degradation analysis and preclinical neuropharmacology models.
- Evidence limits
- Preclinical and analytical publications do not establish human safety or therapeutic performance.
- U.S. context
- FDA has identified limited human safety information and potential immunogenicity concerns in the compounding context.
Identity & technical details
- Identity status
- Reference identity defined
- Sequence
- Thr-Lys-Pro-Arg-Pro-Gly-Pro
- Formula
- C33H57N11O9
- Molecular mass
- 751.9 g/mol
- PubChem CID
- 11765600
Official & primary research sources
SemaxAlso indexed as: Met-Glu-His-Phe-Pro-Gly-ProPeptide analogPreclinical and analytical literature
A synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro.
- Research summary
- Published literature includes sequence characterization and preclinical nervous-system models.
- Evidence limits
- The cited research does not establish an FDA-approved use, human safety conclusion, or material release specification.
- U.S. context
- FDA has identified limited safety information and potential peptide-related immunogenicity concerns in the compounding context.
Identity & technical details
- Identity status
- Reference identity defined
- Sequence
- Met-Glu-His-Phe-Pro-Gly-Pro
- Formula
- C37H51N9O10S
- Molecular mass
- 813.9 g/mol
- PubChem CID
- 9811102
Official & primary research sources
TesamorelinDevelopment code: TH9507Peptide analogFDA-labeled drug reference
A synthetic growth-hormone-releasing factor analog represented by a defined reference substance.
- Research summary
- Official labeling and chemistry databases document the approved drug substance and its pharmacologic class.
- Evidence limits
- Approval of a prescription product does not transfer to an unlabeled research material or establish future lot quality.
- U.S. context
- Current FDA prescribing information controls the approved product. This record is not prescribing information.
Identity & technical details
- Identity status
- Reference identity defined
- Formula
- C221H366N72O67S
- Molecular mass
- 5136 g/mol
- PubChem CID
- 16137828
Official & primary research sources
IpamorelinDevelopment code: NNC 26-0161Peptide analogHuman research literature
A synthetic pentapeptide growth-hormone secretagogue.
- Research summary
- Published work includes human pharmacokinetic and pharmacodynamic research and a controlled postsurgical trial.
- Evidence limits
- A limited clinical literature does not establish broad safety, effectiveness, or identity for independently sourced material.
- U.S. context
- FDA has identified safety concerns and insufficient information for compounded ipamorelin acetate.
Identity & technical details
- Identity status
- Reference identity defined
- Formula
- C38H49N9O5
- Molecular mass
- 711.9 g/mol
- PubChem CID
- 9831659
Official & primary research sources
EpitalonAlso indexed as: Epithalon · Also indexed as: Ala-Glu-Asp-GlyPeptidePreclinical literature
A synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. Epithalon is a common alternate spelling.
- Research summary
- Published literature includes molecular and animal aging models.
- Evidence limits
- Preclinical observations do not establish human longevity, clinical benefit, or a material specification.
- U.S. context
- FDA has identified limited safety information and potential immunogenicity concerns in the compounding context.
Identity & technical details
- Identity status
- Reference identity defined
- Sequence
- Ala-Glu-Asp-Gly
- Formula
- C14H22N4O9
- Molecular mass
- 390.35 g/mol
- PubChem CID
- 219042
Official & primary research sources
Delta sleep-inducing peptideAlso indexed as: DSIP · Also indexed as: EmideltidePeptideLimited human literature
A nonapeptide also indexed as emideltide, with a defined nine-residue sequence.
- Research summary
- Early isolation work established the sequence; a small human sleep study reported weak and possibly incidental effects.
- Evidence limits
- The limited and mixed human literature does not establish therapeutic benefit or a general safety conclusion.
- U.S. context
- FDA has identified insufficient human safety information and potential immunogenicity concerns in the compounding context.
Identity & technical details
- Identity status
- Reference identity defined
- Sequence
- Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
- Formula
- C35H48N10O15
- Molecular mass
- 848.8 g/mol
- PubChem CID
- 68816
Official & primary research sources
ThymalinAlso indexed as: Thymalin peptide complexPeptide complexIdentity review required
Primary literature describes Thymalin as a peptide complex originally isolated from animal tissue, not as one universally fixed molecular entity.
- Research summary
- Published work includes in-vitro studies of a named peptide complex.
- Evidence limits
- A supplier label reading only Thymalin is insufficient to establish composition, sequence, molecular mass, or equivalence to a literature preparation.
- U.S. context
- No approved-product or permitted-use claim is made. Exact source, composition, and analytical definition are required before any material admission.
Identity & technical details
- Identity status
- Composition dependent
Official & primary research sources
SermorelinAlso indexed as: Sermorelin acetate · Also indexed as: GHRH(1-29) analogPeptide analogHuman research literature
A synthetic 29-residue analog of the amino-terminal segment of growth-hormone-releasing hormone. The acetate form requires its own salt documentation.
- Research summary
- Human endocrine research has examined pituitary response to GHRH(1-29)-related material.
- Evidence limits
- A base-compound database record does not establish acetate content, purity, potency, or future lot identity.
- U.S. context
- No current approved-product or permitted-use claim is made by this record.
Identity & technical details
- Identity status
- Reference identity defined
- Formula
- C149H246N44O42S
- Molecular mass
- 3357.9 g/mol
- PubChem CID
- 16132413
Official & primary research sources
BPC-157Also indexed as: Body protection compound 157PeptidePreclinical literature / FDA review
A synthetic 15-residue peptide represented by a defined database reference substance.
- Research summary
- The published record is predominantly preclinical; FDA reviewed BPC-157-related bulk substances in 2026.
- Evidence limits
- Preclinical findings do not establish human effectiveness or safety. Scientific support for one component cannot be transferred to a mixture.
- U.S. context
- FDA identifies limited safety information and potential immunogenicity and impurity-characterization concerns for compounded BPC-157.
Identity & technical details
- Identity status
- Reference identity defined
- Formula
- C62H98N16O22
- Molecular mass
- 1419.5 g/mol
- PubChem CID
- 9941957
Official & primary research sources
TB-500Also indexed as: N-acetyl-LKKTETQ · Also indexed as: Thymosin beta-4 fragment 17-23Peptide fragmentIdentity review required
FDA's current substance record defines TB-500 as the seven-residue thymosin beta-4 fragment LKKTETQ, with N-terminal acetylation. It is not full-length thymosin beta-4.
- Research summary
- FDA's 2026 review evaluates TB-500-related bulk substances and separates the short fragment from full-length thymosin beta-4 literature.
- Evidence limits
- The supplied label also says thymosin beta-4 acetate, which is ambiguous. Full-length thymosin beta-4 evidence cannot be assigned to TB-500 without exact structural documentation.
- U.S. context
- FDA reports that it did not identify published nonclinical in-vivo wound studies for the defined TB-500 fragment and identifies broader safety-data limitations.
Identity & technical details
- Identity status
- Supplier label ambiguous
- Sequence
- N-acetyl-LKKTETQ
Official & primary research sources
AOD9604Also indexed as: AOD-9604 · Also indexed as: Modified growth hormone C-terminal fragmentPeptide fragmentPreclinical literature / FDA review
A modified C-terminal fragment of human growth hormone represented by a defined database record.
- Research summary
- Published research includes metabolic experiments in obese and lean mouse models.
- Evidence limits
- Mouse findings do not establish human effectiveness or safety and should not be conflated with an unlabeled growth-hormone fragment.
- U.S. context
- FDA identifies insufficient safety information for compounded AOD-9604 and notes concerns related to peptide impurities and immunogenicity.
Identity & technical details
- Identity status
- Reference identity defined
- Formula
- C78H123N23O23S2
- Molecular mass
- 1815.1 g/mol
- PubChem CID
- 71300630
Official & primary research sources
5-Amino-1MQAlso indexed as: 5-Amino-1-methylquinolinium · Also indexed as: 5-Amino-1-methylquinolinium iodideSmall moleculePreclinical literature
A quaternary quinolinium small molecule studied as an NNMT inhibitor. It is not a peptide; the counterion must be specified to define the supplied salt.
- Research summary
- Published work includes enzyme, cell, and mouse studies of nicotinamide N-methyltransferase inhibition.
- Evidence limits
- The cited evidence is preclinical. The free cation and iodide salt have different formula and mass records and cannot be treated as unspecified equivalents.
- U.S. context
- No FDA-approved product, human safety conclusion, or permitted-use claim is made by this reference record.
Identity & technical details
- Identity status
- Composition dependent
- Formula
- C10H11IN2
- Molecular mass
- 286.11 g/mol
- PubChem CID
- 66522933
Official & primary research sources
BPC-157 + GHK-Cu + TB-500Also indexed as: Three-component source-list groupComponent groupComponent sources only
A source-list combination of three separately defined components. It has no single molecular identity, formula, or transferable evidence record.
- Research summary
- Review the BPC-157, GHK-Cu, and TB-500 records independently.
- Evidence limits
- Evidence for one component does not establish the behavior, stability, compatibility, safety, or performance of the mixture.
- U.S. context
- No combined-product status or permitted-use claim is made. Exact composition and compatibility evidence would be required before any product review.
Identity & technical details
- Identity status
- Component group
- Components
- BPC-157 / GHK-Cu / TB-500
Official & primary research sources
GHK-Cu + TB-500 + BPC-157 + KPVAlso indexed as: KLOW source-list labelComponent groupComponent sources only
A source-list combination of four separately defined components. The supplier alias is not a scientific identity.
- Research summary
- Review each component record independently; no unified evidence record was identified for this exact group.
- Evidence limits
- Component-level literature cannot establish mixture compatibility, stability, safety, or performance.
- U.S. context
- No combined-product status or permitted-use claim is made. Exact composition and compatibility evidence would be required before any product review.
Identity & technical details
- Identity status
- Component group
- Components
- GHK-Cu / TB-500 / BPC-157 / KPV
Official & primary research sources
BPC-157 + TB-500Also indexed as: Two-component source-list groupComponent groupComponent sources only
A source-list combination of two separately defined peptides. Repeated package ratios in the source list do not create separate scientific identities.
- Research summary
- Review the BPC-157 and TB-500 records independently.
- Evidence limits
- No unified evidence conclusion is assigned to the mixture, and full-length thymosin beta-4 literature is not TB-500 evidence.
- U.S. context
- No combined-product status or permitted-use claim is made. Exact composition and compatibility evidence would be required before any product review.
Identity & technical details
- Identity status
- Component group
- Components
- BPC-157 / TB-500
Official & primary research sources
KPV + GHK-CuAlso indexed as: Two-component source-list groupComponent groupComponent sources only
A source-list combination of a tripeptide and a copper-peptide complex. It has no single molecular identity.
- Research summary
- Review the KPV and GHK-Cu records independently.
- Evidence limits
- Separate component literature does not establish mixture compatibility, copper speciation, stability, safety, or performance.
- U.S. context
- No combined-product status or permitted-use claim is made. Exact composition and compatibility evidence would be required before any product review.
Identity & technical details
- Identity status
- Component group
- Components
- KPV / GHK-Cu